NTRA Stock Analysis: Natera | NASDAQ
Diagnostics & Research | NASDAQ, USA | Market Cap: 46.857m USD | 12M Return: 102.2% | US6323071042 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 366M
Qual. Beats: 0
Rev. Trend: 99.6%
Qual. Beats: 14
Warnings
Tailwinds
Seasonality 11.1 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Natera, Inc. (NTRA) is a molecular diagnostics company that develops and commercializes genetic testing services globally. Its oncology offerings include Signatera, a personalized ctDNA blood test for molecular residual disease (MRD) monitoring and treatment response; Latitude, a blood-based MRD test for colorectal cancer; and Altera, a tissue-based comprehensive genomic profiling assay. In reproductive health, the company provides Panorama (non-invasive prenatal testing), Horizon (carrier screening), and single-gene NIPT products (Fetal Focus and Vistara). Additional services include Anora for miscarriage tissue analysis, Prospera for solid organ transplant rejection assessment, Renasight for kidney disease, and Empower for hereditary cancer screening.
The company distributes its tests through a direct sales force, laboratory distribution partners, and its Constellation cloud-based platform, serving independent and reference laboratories, hospitals, physician practices, research institutions, and pharmaceutical companies. It also maintains a partnership with BGI Genomics for NGS assay development and a collaboration with Diakonos Oncology in melanoma molecular response. The company is classified within the Health Care sector under the Biotechnology sub-industry and trades as a large-cap stock on the NASDAQ following its 2015 IPO.
- Signatera oncology volume drives double-digit revenue growth
- CMS reimbursement expansions accelerate MRD test adoption
- Cash burn narrows as oncology gross margins scale
| Net Income: -192.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -3.25 > 1.0 |
| NWC/Revenue: 40.85% < 20% (prev 53.29%; Δ -12.44% < -1%) |
| CFO/TA 0.09 > 3% & CFO 228.2m > Net Income -192.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.00 > 1.5 & < 3 |
| Outstanding Shares: last quarter (143.3m) vs 12m ago 5.05% < -2% |
| Gross Margin: 65.30% > 18% (prev 62.91%; Δ 2.40% > 0.5%) |
| Asset Turnover: 122.6% > 50% (prev 111.8%; Δ 10.85% > 0%) |
| Interest Coverage Ratio: -24.51 > 6 (EBIT TTM -244.5m / Interest Expense TTM 9.97m) |
| A: 0.42 (Total Current Assets 1.66b - Total Current Liabilities 553.2m) / Total Assets 2.66b |
| B: -1.10 (Retained Earnings -2.93b / Total Assets 2.66b) |
| C: -0.11 (EBIT TTM -244.5m / Avg Total Assets 2.21b) |
| D: 2.18 (Book Value of Equity 1.82b / Total Liabilities 836.0m) |
| Altman-Z'' = 0.68 = B |
| DSRI: 0.99 (Receivables 422.0m/309.2m, Revenue 2.71b/1.96b) |
| GMI: 0.96 (GM 62.91% / 65.30%) |
| AQI: 8.86 (AQ_t 0.21 / AQ_t-1 0.02) |
| SGI: 1.38 (Revenue 2.71b / 1.96b) |
| TATA: -0.16 (NI -192.3m - CFO 228.2m) / TA 2.66b) |
| Beneish M = 1.85 (Cap -4..+1) = D |
As of August 21, 2026, the stock is trading at USD 324.84 with a total of 1,738,289 shares traded. Over the past week, the price has changed by +4.52%, over one month by +23.69%, over three months by +58.52% and over the past year by +102.22%.
Current recommended Stop Loss: 308.30 (which is 5.1% or 1.3 ATR below the current price).
Natera has received a consensus analysts rating of 4.48. Therefore, it is recommended to buy NTRA.
- StrongBuy: 12
- Buy: 8
- Hold: 0
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 330.6 | 1.8% |
P/S = 17.3091
P/B = 24.6656
Revenue TTM = 2.71b USD
EBIT TTM = -244.5m USD
EBITDA TTM = -179.1m USD
Long Term Debt = 143.1m USD (estimated: total debt 238.5m - short term 95.4m)
Short Term Debt = 95.4m USD (from shortTermDebt, last quarter)
Debt = 396.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 158.2m
Net Debt = -694.8m USD (calculated: Debt 396.7m - CCE 1.09b)
Enterprise Value = 46.2b USD (46.9b + Debt 396.7m - CCE 1.09b)
Interest Coverage Ratio = -24.51 (Ebit TTM -244.5m / Interest Expense TTM 9.97m)
EV/FCF = 643.9x (Enterprise Value 46.2b / FCF TTM 71.7m)
FCF Yield = 0.16% (FCF TTM 71.7m / Enterprise Value 46.2b)
FCF Margin = 2.65% (FCF TTM 71.7m / Revenue TTM 2.71b)
Net Margin = -7.11% (Net Income TTM -192.3m / Revenue TTM 2.71b)
Gross Margin = 65.30% ((Revenue TTM 2.71b - Cost of Revenue TTM 939.2m) / Revenue TTM)
Gross Margin QoQ = 64.46% (prev 64.80%)
Tobins Q-Ratio = 17.37 (Enterprise Value 46.2b / Total Assets 2.66b)
Interest Expense / Debt = 2.51% (Interest Expense 9.97m / Debt 396.7m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -193.2m (EBIT -244.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.00 (Total Current Assets 1.66b / Total Current Liabilities 553.2m)
Debt / Equity = 0.22 (Debt 396.7m / totalStockholderEquity, last quarter 1.82b)
Debt / EBITDA = 3.88 (negative EBITDA) (Net Debt -694.8m / EBITDA -179.1m)
Debt / FCF = -9.69 (Net Debt -694.8m / FCF TTM 71.7m)
Total Stockholder Equity = 1.64b (last 4 quarters mean from totalStockholderEquity)
RoA = -8.71% (Net Income -192.3m / Total Assets 2.66b)
RoE = -11.73% (Net Income TTM -192.3m / Total Stockholder Equity 1.64b)
RoCE = -13.71% (EBIT -244.5m / Capital Employed (Equity 1.64b + L.T.Debt 143.1m))
RoIC = -9.36% (negative operating profit) (NOPAT -193.2m / Invested Capital 2.06b)
WACC = 8.71% (E(46.9b)/V(47.3b) * Re(8.77%) + D(396.7m)/V(47.3b) * Rd(2.51%) * (1-Tc(0.21)))
Discount Rate = 8.77% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 96.30 | Cagr: 7.87%
[DCF] Terminal Value 71.75% ; FCFF base≈84.8m ; Y1≈74.4m ; Y5≈60.1m
[DCF] Fair Price = 11.14 (EV 910.3m - Net Debt -694.8m = Equity 1.61b / Shares 144.1m; r=8.71% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: 99.61 | Revenue CAGR: 44.20% | SUE: 4.0 | # QB: 14
EPS current Quarter (2026-09-30): EPS=-0.24 | Chg30d=+36.18% | Revisions=+58% | Analysts=13
EPS current Year (2026-12-31): EPS=-1.41 | Chg30d=+17.70% | Revisions=+62% | GrowthEPS=+7.4% | GrowthRev=+25.7%
EPS next Year (2027-12-31): EPS=-0.11 | Chg30d=+45.68% | Revisions=+18% | GrowthEPS=+92.1% | GrowthRev=+19.7%
[Analyst] Revisions Ratio: +57% (up=22, down=5)